SBL03 was formulated as an ophthalmic gel for non-invasive topical delivery. Its unique ability to infiltrate eye tissues effectively and protect ret ...

The Gonzales Lab at UNR Med, led by Albert Gonzales, Ph.D., assistant professor of physiology and cell biology, spearheaded ...

The global macular degeneration treatment market size was valued at USD 10.06 billion in 2024 and it is projected to reach ...

In this Healio Video Perspective from Retina 2025, Ramiro Ribeiro, MD, PhD, of EyePoint Pharmaceuticals, discusses Duravyu, a vorolanib intravitreal insert. According to Ribeiro, in the DAVIO 2 trial, ...

Macular degeneration is a leading cause of vision loss for people over 50, but there are ways to help protect your eyesight.

Initial interim 52-week results from Phase 2b Population Extension cohort of PRISM clinical trial to be presented by Dante Pieramici, M.D., a Principal Investigator in PRISM, at Angiogenesis, ...

The research illustrated “substantial benefits” of enhanced optometry services in community practices handling conditions ...

Introduction The eye's macula is impacted by macular degeneration, a neurodegenerative condition. Macular degeneration will cause loss of centr ...

Medication is sometimes necessary to treat eye conditions and vision problems. Of course, this is highly dependent on the ...

Pegcetacoplan (Syfovre) is now approved in Australia for treating geographic atrophy (GA) secondary to age-related macular ...

HDL cholesterol levels demonstrate a U-shaped association with AMD, in which both high and low levels elevate risk.

Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) announced today that the Therapeutic Goods Administration (TGA) has approved SYFOVRE® (pegcetacoplan) for ...